Pipeline plays for BMS, Rigel; plus J&J’s vaccine panel & access for Africa: a BioCentury podcast
On the latest BioCentury This Week podcast, BioCentury editors analyze how BMS is managing its pipeline, spotlight Rigel’s deal with Lilly, look towards the Feb. 26 FDA advisory panel meeting to discuss J&J’s COVID-19 vaccine and discuss initiatives to improve Africans’ access to cancer drugs.
Senior Editor Lauren Martz and Editor in Chief Simone Fishburn discuss how Bristol Myers Squibb Co. (NYSE:BMY) is building out its early-stage pipeline to find its next big oncology drug and stave off revenue losses from upcoming patent cliffs by taking a broad look at cancer’s hottest targets and technologies.
Fishburn digs into the decision tree behind the deal Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) made with Eli Lilly and Co. (NYSE:LLY) for the biotech’s clinical RIPK1 program. It’s an “old school” deal, according to Fishburn, who says that Rigel entered the deal to fund its next program, for IRAK4, rather than, for example, partner with a pharma to gain strategic and operational help.